10-K Filing

Xenetic Biosciences, Inc. CIK: 1534525 FY 2019

Filing Information

Form Type	10-K
Accession Number	`0001683168-20-000967`
Period End Date	20191231
Filing Date	20200326
Fiscal Year	2019
Fiscal Period	FY
XBRL Instance	xbio-20191231.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 55 Income Statement 28 Cash Flow Statement 58 Stockholders Equity 19

Balance Sheet 55 line items

Line Item	Tag	Value	Unit	Period
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	12.50M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	12.50M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	6.09M	shares	Point-in-time
Cash	`Cash`	$571.61K	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	810,856.00	shares	Point-in-time
Cash	`Cash`	$10.37M	USD	Point-in-time
Restricted cash	`RestrictedCash`	-	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	6.07M	shares	Point-in-time
Restricted cash	`RestrictedCash`	$66.51K	USD	Point-in-time
Prepaid expenses and other	`PrepaidExpenseAndOtherAssetsCurrent`	$722.08K	USD	Point-in-time
Prepaid expenses and other	`PrepaidExpenseAndOtherAssetsCurrent`	$555.86K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$11.09M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$1.19M	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$4.96K	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$757.00	USD	Point-in-time
Goodwill	`Goodwill`	-	USD	Point-in-time
Goodwill	`Goodwill`	$3.28M	USD	Point-in-time
Goodwill	`Goodwill`	$3.28M	USD	Point-in-time
Indefinite-lived intangible assets	`IndefiniteLivedIntangibleAssetsExcludingGoodwill`	$9.24M	USD	Point-in-time
Indefinite-lived intangible assets	`IndefiniteLivedIntangibleAssetsExcludingGoodwill`	$9.24M	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$705.66K	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$1.21M	USD	Point-in-time
Total assets	`Assets`	$14.43M	USD	Point-in-time
Total assets	`Assets`	$21.55M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$931.13K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$934.15K	USD	Point-in-time
Accrued expenses and other current liabilities	`AccountsPayableAndAccruedLiabilitiesCurrent`	$665.64K	USD	Point-in-time
Accrued expenses and other current liabilities	`AccountsPayableAndAccruedLiabilitiesCurrent`	$484.03K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.60M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.42M	USD	Point-in-time
Deferred tax liability	`DeferredTaxLiabilitiesNoncurrent`	$2.92M	USD	Point-in-time
Deferred tax liability	`DeferredTaxLiabilitiesNoncurrent`	$2.92M	USD	Point-in-time
Total liabilities	`Liabilities`	$4.52M	USD	Point-in-time
Total liabilities	`Liabilities`	$4.33M	USD	Point-in-time
Commitments and contingent liabilities (Note 13)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingent liabilities (Note 13)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Common stock, $0.001 par value; 12,500,000 shares authorized as of December 31, 2019 and December 31, 2018; 6,092,432 and 810,856 shares issued as of December 31, 2019 and December 31, 2018, respectively; 6,065,441 and 783,865 shares outstanding as of December 31, 2019 and December 31, 2018, respectively	`CommonStockValue`	$6.09K	USD	Point-in-time
Common stock, $0.001 par value; 12,500,000 shares authorized as of December 31, 2019 and December 31, 2018; 6,092,432 and 810,856 shares issued as of December 31, 2019 and December 31, 2018, respectively; 6,065,441 and 783,865 shares outstanding as of December 31, 2019 and December 31, 2018, respectively	`CommonStockValue`	$811.00	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapital`	$188.24M	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapital`	$168.17M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-153.23M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-166.01M	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$253.73K	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$253.73K	USD	Point-in-time
Treasury stock	`TreasuryStockValue`	$5.28M	USD	Point-in-time
Treasury stock	`TreasuryStockValue`	$5.28M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$9.91M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$17.21M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$14.30M	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$14.43M	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$21.55M	USD	Point-in-time

Income Statement 28 line items

Line Item	Tag	Value	Unit	Period
Total revenues	`Revenues`	-	USD	Annual
Total revenues	`Revenues`	$17.07K	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$2.88M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$4.89M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$4.73M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$4.39M	USD	Annual
Goodwill impairment (Note 6)	`GoodwillImpairmentLoss`	-	USD	Annual
Goodwill impairment (Note 6)	`GoodwillImpairmentLoss`	$3.28M	USD	Annual
Total operating costs and expenses	`OperatingExpenses`	$7.28M	USD	Annual
Total operating costs and expenses	`OperatingExpenses`	$12.90M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-12.89M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-7.28M	USD	Annual
Other income (expense)	`OtherNonoperatingIncomeExpense`	$3.31K	USD	Annual
Other income (expense)	`OtherNonoperatingIncomeExpense`	$-24.64K	USD	Annual
Interest income, net	`InterestIncomeExpenseNet`	$108.49K	USD	Annual
Interest income, net	`InterestIncomeExpenseNet`	$509.00	USD	Annual
Total other income (expense)	`NonoperatingIncomeExpense`	$111.80K	USD	Annual
Total other income (expense)	`NonoperatingIncomeExpense`	$-24.13K	USD	Annual
Net loss	`NetIncomeLoss`	$-7.30M	USD	Annual
Net loss	`NetIncomeLoss`	$-12.78M	USD	Annual
Deemed dividend	`PreferredStockDividendsIncomeStatementImpact`	-	USD	Annual
Deemed dividend	`PreferredStockDividendsIncomeStatementImpact`	$5.28M	USD	Annual
Net loss applicable to common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-7.30M	USD	Annual
Net loss applicable to common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-18.06M	USD	Annual
Basic and diluted loss per share	`EarningsPerShareBasicAndDiluted`	$-6.33	USD	Annual
Basic and diluted loss per share	`EarningsPerShareBasicAndDiluted`	$-9.66	USD	Annual
Weighted-average shares of common stock outstanding, basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	2.85M	shares	Annual
Weighted-average shares of common stock outstanding, basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	756,015.00	shares	Annual

Cash Flow Statement 58 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-7.30M	USD	Annual
Net loss	`NetIncomeLoss`	$-12.78M	USD	Annual
Acquired in-process research and development	`AcquiredInprocessResearchAndDevelopment`	$3.03M	USD	Annual
Acquired in-process research and development	`AcquiredInprocessResearchAndDevelopment`	-	USD	Annual
Goodwill impairment	`GoodwillImpairmentLoss`	-	USD	Annual
Goodwill impairment	`GoodwillImpairmentLoss`	$3.28M	USD	Annual
Depreciation	`Depreciation`	$15.83K	USD	Annual
Depreciation	`Depreciation`	$4.20K	USD	Annual
Amortization of right of use asset	`OtherDepreciationAndAmortization`	$23.29K	USD	Annual
Amortization of right of use asset	`OtherDepreciationAndAmortization`	-	USD	Annual
Gain on sale of property and equipment	`GainLossOnSaleOfPropertyPlantEquipment`	$15.44K	USD	Annual
Gain on sale of property and equipment	`GainLossOnSaleOfPropertyPlantEquipment`	$2.00K	USD	Annual
Share-based expense	`ShareBasedCompensation`	$806.09K	USD	Annual
Share-based expense	`ShareBasedCompensation`	$1.36M	USD	Annual
Vendor share-based payments	`VendorShareBasedPayments`	$47.43K	USD	Annual
Vendor share-based payments	`VendorShareBasedPayments`	$69.71K	USD	Annual
Issuance of warrants in connection with reverse stock split	`IssuanceOfWarrantsInConnectionWithReverseStockSplit`	-	USD	Annual
Issuance of warrants in connection with reverse stock split	`IssuanceOfWarrantsInConnectionWithReverseStockSplit`	$63.54K	USD	Annual
Prepaid expenses and other assets	`IncreaseDecreaseInAccountsAndOtherReceivables`	$653.56K	USD	Annual
Prepaid expenses and other assets	`IncreaseDecreaseInAccountsAndOtherReceivables`	$251.80K	USD	Annual
Accounts payable, accrued expenses and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-343.88K	USD	Annual
Accounts payable, accrued expenses and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-227.96K	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-6.40M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-6.46M	USD	Annual
Proceeds from sale of property and equipment	`ProceedsFromSaleOfPropertyPlantAndEquipment`	$2.00K	USD	Annual
Proceeds from sale of property and equipment	`ProceedsFromSaleOfPropertyPlantAndEquipment`	$22.50K	USD	Annual
Net cash provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$22.50K	USD	Annual
Net cash provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$2.00K	USD	Annual
Net proceeds from issuance of common stock and warrants in public offering	`ProceedsFromIssuanceOrSaleOfEquity`	-	USD	Annual
Net proceeds from issuance of common stock and warrants in public offering	`ProceedsFromIssuanceOrSaleOfEquity`	$13.42M	USD	Annual
Net proceeds from issuance of common stock and warrants in registered direct offering	`ProceedsFromIssuanceOrSaleOfEquity2`	$2.70M	USD	Annual
Net proceeds from issuance of common stock and warrants in registered direct offering	`ProceedsFromIssuanceOrSaleOfEquity2`	-	USD	Annual
Proceeds from exercise of warrants	`ProceedsFromWarrantExercises`	$1.48M	USD	Annual
Proceeds from exercise of warrants	`ProceedsFromWarrantExercises`	$6.21K	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$1.48M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$16.13M	USD	Annual
Net change in cash and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	$-4.96M	USD	Annual
Net change in cash and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	$9.73M	USD	Annual
Cash and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$638.12K	USD	Point-in-time
Cash and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$5.60M	USD	Point-in-time
Cash and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$10.37M	USD	Point-in-time
Cash and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$638.12K	USD	Point-in-time
Cash and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$5.60M	USD	Point-in-time
Cash and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$10.37M	USD	Point-in-time
Cash paid for interest	`InterestPaidNet`	$599.00	USD	Annual
Cash paid for interest	`InterestPaidNet`	$8.00	USD	Annual
Right of use assets obtained in exchange for lease obligations	`RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability`	$43.33K	USD	Annual
Right of use assets obtained in exchange for lease obligations	`RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability`	-	USD	Annual
Issuance of common stock to vendor	`IssuanceOfCommonStockToVendor`	-	USD	Annual
Issuance of common stock to vendor	`IssuanceOfCommonStockToVendor`	$7.00	USD	Annual
Issuance of common stock to acquire in-process research and development	`IssuanceOfCommonStockToAcquireInprocessResearchAndDevelopment`	$3.03M	USD	Annual
Issuance of common stock to acquire in-process research and development	`IssuanceOfCommonStockToAcquireInprocessResearchAndDevelopment`	-	USD	Annual
Issuance of common stock to adjust for Reverse Stock Split	`IssuanceOfCommonStockToAdjustForReverseStockSplit`	-	USD	Annual
Issuance of common stock to adjust for Reverse Stock Split	`IssuanceOfCommonStockToAdjustForReverseStockSplit`	$1.00	USD	Annual
Issuance of common stock from cashless exercise of purchase warrants	`IssuanceOfCommonStockFromCashlessExerciseOfPurchaseWarrants`	$2.20K	USD	Annual
Issuance of common stock from cashless exercise of purchase warrants	`IssuanceOfCommonStockFromCashlessExerciseOfPurchaseWarrants`	-	USD	Annual
Conversion of Series B preferred stock to common stock	`ConversionOfSeriesBPreferredStockToCommonStock`	-	USD	Annual
Conversion of Series B preferred stock to common stock	`ConversionOfSeriesBPreferredStockToCommonStock`	$316.00	USD	Annual

Stockholders Equity 19 line items

Line Item	Tag	Value	Unit	Period
Beginning balance, value	`StockholdersEquity`	$9.91M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$17.21M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$14.30M	USD	Point-in-time
Exercise of warrants, value	`StockIssuedForExerciseOfWarrantsValue`	$1.48M	USD	Annual
Common stock and warrants issued new, value	`StockIssuedDuringPeriodValueNewIssues`	$16.12M	USD	Annual
Issuance of common stock in connection with purchase of in-process research and development, value	`StockIssuedDuringPeriodValuePurchaseOfAssets`	$3.03M	USD	Annual
Exercise of pre-funded warrant, value	`ExerciseOfPrefundedWarrantValue`	$6.21K	USD	Annual
Issuance of common stock to vendor, value	`StockIssuedDuringPeriodValueIssuedForServices`	$69.71K	USD	Annual
Issuance of warrants in connection with reverse stock split, value	`AdjustmentsToAdditionalPaidInCapitalStockSplit`	$-63.54K	USD	Annual
Deemed dividend related to Series B Preferred Stock down round provision	`DeemedDividendRelatedToSeriesBPreferredStockDownRoundProvision`	$5.28M	USD	Annual
Accretion of deemed dividend related to Series B Preferred Stock down round provision	`OtherPreferredStockDividendsAndAdjustments`	$5.28M	USD	Annual
Share-based expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$806.09K	USD	Annual
Share-based expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$1.36M	USD	Annual
Common stock awards to vendors	`AdjustmentsToAdditionalPaidInCapitalOther`	$47.43K	USD	Annual
Net loss	`NetIncomeLoss`	$-7.30M	USD	Annual
Net loss	`NetIncomeLoss`	$-12.78M	USD	Annual
Ending balance, value	`StockholdersEquity`	$9.91M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$17.21M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$14.30M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.